Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Boosted by Tidal Investments LLC

Tidal Investments LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 75.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,544 shares of the biopharmaceutical company's stock after acquiring an additional 8,811 shares during the period. Tidal Investments LLC's holdings in Alnylam Pharmaceuticals were worth $5,650,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Los Angeles Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock valued at $37,684,000 after acquiring an additional 135,829 shares during the last quarter. Breakwater Capital Group acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $249,000. Sanctuary Advisors LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $578,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Alnylam Pharmaceuticals by 22.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company's stock worth $20,165,000 after purchasing an additional 13,422 shares in the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $7,009,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.1 %

Shares of ALNY stock traded up $0.18 during mid-day trading on Friday, reaching $245.44. The company's stock had a trading volume of 592,047 shares, compared to its average volume of 860,965. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The firm has a market capitalization of $31.66 billion, a PE ratio of -93.68 and a beta of 0.32. The company's 50 day simple moving average is $267.01 and its 200-day simple moving average is $248.16. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the previous year, the business earned $1.15 earnings per share. Alnylam Pharmaceuticals's revenue for the quarter was down 33.3% compared to the same quarter last year. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Ratings Changes

ALNY has been the subject of several recent research reports. Needham & Company LLC reissued a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Wolfe Research cut Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research report on Tuesday, November 12th. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th. TD Cowen raised their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Finally, William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $298.09.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the firm's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Pushkal Garg sold 1,752 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the transaction, the chief marketing officer now directly owns 15,705 shares in the company, valued at approximately $3,941,955. The trade was a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,122 shares of company stock valued at $2,540,455. Corporate insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.